Nutritional compositions and uses thereof

Abstract

The invention relates to a nutritional composition and application thereof. The nutritional composition comprises medium-chain and long-chain fatty acid triglyceride and a milk fat globule film, wherein the weight ratio of the medium-chain and long-chain fatty acid triglyceride to the milk fat globule film is 0.1: 1 to 50: 1. The nutritional composition disclosed by the invention can play a role in obviously improving sleep.

Description

Technical Field

[0001] The present invention relates to the field of food and medicine, and in particular to a nutritional composition comprising medium-chain and long-chain fatty acid triglycerides and milk fat globule membrane, food and medicine comprising the nutritional composition, use of the nutritional composition or the food for non-therapeutic purposes of improving sleep, and use of the nutritional composition in preparing medicines for improving sleep. Background Art

[0002] Good sleep can help people relieve physical strength, improve immune function, and build cognitive ability. It is a physiological need necessary for people to survive. Especially for infants and young children, who are in a critical stage of growth and development, good sleep is crucial to promote their physical growth, nervous system development, and intellectual development. If there are serious problems with the sleep quality of infants and young children, such as disturbed wakefulness or bedtime rhythms, it will not only affect their physical growth and intellectual development, but also have a certain impact on their emotions and behaviors. Infants' sleep-wake patterns and sleep quality will affect the mother's sleep quality and emotions to a certain extent (Chen Jinshi. Study on the impact of early sleep intervention strategies on infants' physical growth and sleep-wake patterns [J]. Journal of Aerospace Medicine, 2023, 34(04): 409-411).

[0003] In view of the above problems, it is of great significance to develop ways to effectively improve sleep. Summary of the invention

[0004] The present invention is made in view of the above problems existing in the prior art.

[0005] In a first aspect, the present invention relates to a nutritional composition comprising: medium- and long-chain triacylglycerol (MLCT); and milk fat globule membrane (MFGM, Milk Fat Globule Membrane, also commonly known as MFGM milk lecithin), wherein the weight ratio of MLCT to MFGM is 0.1:1 to 50:1.

[0006] The inventors unexpectedly discovered in their research that when MLCT and MFGM are used in combination at a specific weight ratio, they exhibit a synergistic effect in improving sleep, especially in terms of the amount of wakefulness activity and the total wakefulness time. The effect of their combined use is better than the effect of the same total amount of MLCT alone, and is also better than the effect of the same total amount of MFGM alone.

[0007] In a second aspect, the present invention relates to a food product comprising the nutritional composition according to the first aspect of the present invention.

[0008] In a third aspect, the present invention relates to a medicament comprising the nutritional composition according to the first aspect of the present invention.

[0009] In a fourth aspect, the present invention relates to the use of the nutritional composition according to the first aspect of the invention or the food according to the second aspect of the invention for the non-therapeutic purpose of improving sleep.

[0010] In a fifth aspect, the present invention relates to use of the nutritional composition according to the first aspect of the present invention in the preparation of a medicament for improving sleep. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] In order to more clearly illustrate the technical solution of the present invention, the following will briefly describe the drawings required for describing the embodiments. It should be understood that these drawings are only for the convenience of technicians to understand the present invention more easily, and are not intended to limit the scope of the present invention.

[0012] Figure 1 The results of statistical analysis of the amount of awakening activity (A and C) and total awakening time (B and D) of zebrafish in the normal control group, model control group, positive control group using L-Tryptophan, and experimental control group using MLCT or MFGM alone are presented. Compared with the model control group: *p < 0.05, **p < 0.01, *** indicates p < 0.001.

[0013] Figure 2 The results of statistical analysis of the total wakefulness time (A) and total wakefulness activity (B) of zebrafish in the normal control group, model control group, positive control group using L-Tryptophan, experimental control group using MLCT or MFGM alone, and experimental group using MLCT and MFGM in combination are presented, compared with the model control group: *** indicates p < 0.001. DETAILED DESCRIPTION

[0014] In order to make the invention purpose, technical solution and beneficial technical effect of the present application clearer, the present application will be described in detail below. It should be noted that the various aspects, features, implementation methods and advantages described in the present application may be compatible and / or may be combined together.

[0015] Unless otherwise specified, the meanings of the technical terms or scientific terms in this specification are the same as those generally understood by those skilled in the art.

[0016] In the present application, unless otherwise specified, the temperature is room temperature (25° C.), the atmosphere is air, and the pressure is atmospheric pressure.

[0017] In the present application, the term "medium-chain fatty acid" refers to fatty acids with 6-12 carbon atoms in the carbon chain, such as caproic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, etc.; the term "long-chain fatty acid" refers to fatty acids with more than 14 carbon atoms, generally 14-30 carbon atoms, in the carbon chain, such as myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, etc. The terms "medium-chain fatty acid triglyceride" and "long-chain fatty acid triglyceride" refer to the esterification reaction products of "medium-chain fatty acid" and "long-chain fatty acid" with glycerol, respectively; the term "medium-long chain fatty acid triglyceride" refers to triglycerides containing both medium-chain fatty acid residues and long-chain fatty acid residues in the molecular structure.

[0018] In this application, "special food" refers to special types of food for specific groups of people, such as "the elderly, the young, and the sick", including three categories: health food, infant formula, and special medical purpose formula food.

[0019] The present invention relates to a nutritional composition comprising MLCT and MFGM, a food and a medicine comprising the nutritional composition, use of the nutritional composition or the food for non-therapeutic purposes of improving sleep, and use of the nutritional composition in preparing a medicine for improving sleep. The present invention will be described in detail below.

[0020] Nutritional composition A first aspect of the present invention relates to a nutritional composition comprising: medium-chain fatty acid triglycerides (MLCT); and milk fat globule membrane (MFGM), wherein the weight ratio of MLCT to MFGM is 0.1:1 to 50:1.

[0021] Among the components included in the nutritional composition of the present invention, medium-chain triglycerides (MLCT) are structural lipids that contain medium-chain fatty acids and long-chain fatty acids on a class of triglyceride molecules, which have different physicochemical properties, metabolic characteristics and nutritional value from long-chain triglycerides (LCT) or medium-chain triglycerides (MCT). Studies (see, for example, Yuan Tinglan, Medium-chain triglyceride composition and metabolic characteristics of breast milk fat [D], Jiangnan University, 2021) show that medium-chain triglycerides (MLCT) are not simply equivalent to a physical mixture of long-chain triglycerides (LCT) and medium-chain triglycerides (MCT) (of course, they are not equivalent to a simple mixture of long-chain fatty acids and medium-chain fatty acids), and the latter does not have the physicochemical properties, metabolic characteristics and nutritional value of the former.

[0022] Among the components contained in the nutritional composition of the present invention, the term "medium-chain triglyceride" or "MLCT" is a special triglyceride, in which medium-chain fatty acids and long-chain fatty acids coexist on the triglyceride backbone. According to the relevant provisions of the "New Resource Food Management Measures", MLCT is made from edible vegetable oil and medium-chain triglycerides, through lipase transesterification reaction, distillation separation, decolorization, deodorization and other processes.

[0023] Among the components contained in the nutritional composition of the present invention, "milk fat globule membrane" or "MFGM" in English is a complex biological membrane structure present in breast milk. MFGM is a complex three-layer phospholipid protein membrane composed of polar lipids, cholesterol and proteins, etc., which is encapsulated on the surface of milk fat droplets. In principle, there is no particular limitation on the source of the MFGM of the present invention. It can usually be obtained by extraction from animal milk or its products. In some preferred embodiments, such animal milk or its products can be cow's milk, goat's milk, camel's milk, horse's milk or dairy products based on them (such as cheese), etc. More preferably, it can be extracted from cow's milk, including bovine colostrum or bovine normal milk.

[0024] The present invention does not specifically limit the method for extracting MFGM from the above-mentioned animal milk or its products. For example, the method of acidification precipitation-centrifugation-isoelectric point enrichment-drying can be used, or the existing membrane filtration method can be used to separate and obtain MFGM.

[0025] In addition, MFGM can also be obtained through commercial products, including MFGM whey protein powder and MFGM milk protein powder. MFGM whey protein powder refers to a powdered product containing MFGM made from raw milk or whey through separation, concentration, drying and other processes. MFGM milk protein powder refers to a powdered product containing MFGM made from raw milk or cream through separation, concentration, drying and other processes.

[0026] Commercial sources of MFGM for the present invention include Lacprodan MFGM-10, Lacprodan PL-20, Cor-Power SM2, lipid-rich MFGM fraction or buttermilk powder concentrate BPC50, BPC60, G600, PC700, HilmarCor-Power WPC7500MEGM ENRICHED WPC, etc.

[0027] The inventors unexpectedly discovered in their research that MLCT and MFGM, when used in combination at a specific weight ratio, exhibit a synergistic effect in improving sleep, especially in terms of the amount of wakefulness activity and the total wakefulness time. The effect of their combined use is better than the effect of the same total amount of MLCT alone, and is also better than the effect of the same total amount of MFGM alone.

[0028] The present invention has no special requirements for the MLCT used, and the MLCT commonly used in the art can be used. MLCT can be used in a pure form or in an impure form rich in MLCT.

[0029] In some embodiments, the MLCT used in the present invention comprises C6-C 12 (e.g. C6, C7, C8, C9, C 10 , C 11 , C 12 , or the range defined by any two thereof) fatty acid residues and C 14 -C 30 (For example, C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , or the range defined by any two thereof) fatty acid residues, wherein: the C6-C 12 The fatty acid residue is derived from one or more of the following: caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, dodecanoic acid, etc., preferably caproic acid, caprylic acid, capric acid and lauric acid; and / or the C 14 -C 30 The fatty acid residue is derived from one or more of the following: myristic acid, palmitic acid, heptadecanoic acid, oleic acid, linoleic acid, stearic acid, nonadecanoic acid, eicosapentaenoic acid, heneicosanoic acid, docosatetraenoic acid, docosahexaenoic acid, tricosanoic acid, tetracosenoic acid, eicosapentaenoic acid, hexacoshexaenoic acid, arachidonic acid, etc., preferably myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid.

[0030] In some embodiments, the C6-C 12 The fatty acid residues on the C14 -C 30 The weight ratio of fatty acid residues is 0.124 to 2.000. As an example, the C6-C 12 The fatty acid residues on the C 14 -C 30 The weight ratio of the fatty acid residues may be 0.124, 0.125, 0.130, 0.140, 0.150, 0.160, 0.170, 0.180, 0.190, 0.200, 0.300, 0.400, 0.500, 0.600, 0.700, 0.800, 0.900, 1.000, 1.100, 1.200, 1.300, 1.400, 1.500, 1.600, 1.700, 1.800, 1.900, 2.000, or within the range defined by any two of them.

[0031] MFGM may be derived from any substance containing MFGM such as raw cow's milk and / or raw goat's milk and / or whole milk powder and / or demineralized whey powder and / or whey protein powder and / or concentrated whey protein powder (MFGM) and / or MFGM powder.

[0032] In an embodiment, in the nutritional composition of the present invention, the weight ratio of the MLCT to the MFGM is 0.1: 1 to 50: 1. When the weight ratio of the MLCT to the MFGM is within the above range, MFGM and MLCT exhibit a synergistic effect in improving sleep. As an example, the weight ratio of the MLCT to the MFGM can be 0.1:1, 0.2:1, 0.3:1, 0.4:1, 0.45:1, 0.48:1, 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 7.5:1, 7.74:1, 8:1, 9:1, 10:1, 12:1, 14:1, 16:1, 18:1, 20:1, 22:1, 24:1, 26:1, 28:1, 30:1, 32:1, 34:1, 36:1, 38:1, 40:1, 42:1, 44:1, 46:1, 48:1, 50:1, or within the range defined by any two of them.

[0033] Preferably, the weight ratio of the MLCT to the MFGM is 0.2:1 to 40:1; when the weight ratio of the MLCT to the MFGM is within this range, the synergistic effect of MFGM and MLCT in improving sleep, especially the amount of wakefulness activity and the total wakefulness time is more obvious.

[0034] More preferably, the weight ratio of the MLCT to the MFGM is 0.4:1 to 24:1; when the weight ratio of the MLCT to the MFGM is within this range, the synergistic effect of MFGM and MLCT in improving sleep, especially the amount of wakefulness activity and the total wakefulness time is more obvious.

[0035] Further preferably, the weight ratio of the MLCT to the MFGM is 0.4:1 to 8:1; when the weight ratio of the MLCT to the MFGM is within this range, the synergistic effect of MFGM and MLCT in improving sleep, especially the amount of wakefulness activity and the total wakefulness time is more obvious.

[0036] Even more preferably, the weight ratio of the MLCT to the MFGM is 1:1 to 5:1; when the weight ratio of the MLCT to the MFGM is within this range, the synergistic effect of MFGM and MLCT in improving sleep, especially the amount of wakefulness activity and the total wakefulness time is more obvious.

[0037] In some embodiments, the nutritional composition of the present invention may consist of medium- and long-chain fatty acid esters and MFGM.

[0038] food

[0039] A second aspect of the present invention provides a food comprising the nutritional composition according to the first aspect of the present invention.

[0040] In some embodiments, the food may be, for example, a functional food, a health food, or a health product.

[0041] In some embodiments, the food is an infant food such as an infant formula.

[0042] In some embodiments, the food is a common food or a special food. As an example, the food can be selected from dairy products, candies, beverages, bread and biscuits, for example, the food can be selected from milk powder or fermented food. In some embodiments, the milk powder is infant formula milk powder.

[0043] In some embodiments, the MLCT content can be 0.1% to 30.0% based on the dry weight of the food (after deducting water). As an example, the MLCT content can be 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, 30.0 dry basis weight %, or any two thereof. And in a further embodiment, the content of MFGM is converted according to a ratio.

[0044] In some embodiments, the MFGM content may be 0.1 to 30.0% based on the dry weight of the food (after deducting the moisture content). As an example, the MFGM content may be 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 0, 27.5, 28.0, 28.5, 29.0, 29.5, 30.0, 31.0, 32.0, 33.5, 34.0, 35.5, 36.0, 37.5, 38.0, 39.0, 40.5, 41.0, 42.5, 43.0, 44.5, 45.0, 46.5, 47.0, 48.5, 49.0, 50.5, 51.0, 52.5, 53.0, 54.5, 55.0, 56.5, 57.0, 58.5, 59.

[0045] Here, the weight % based on the food may be based on the total weight of the food or the dry weight of the food.

[0046] In addition, it is easy for those skilled in the art to understand that, in addition to the nutritional composition of the first aspect of the present invention, the food also includes one or more selected from the following: raw milk, desalted whey powder, concentrated whey protein, lactose, edible vegetable blending oil, oligofructose, oligogalactose, nucleotides, choline, vitamins, minerals, DHA and taurine.

[0047] For example, when the food is milk powder, in addition to the nutritional composition described in the first aspect of the present invention, the milk powder may also include proteins such as α-lactalbumin, MFGM; carbohydrates such as lactose; lipids; minerals such as calcium, iron, phosphorus, etc.; vitamins; other additives such as whey powder, choline bitartrate, docosahexaenoic acid, arachidonic acid, walnut oil, etc.

[0048] The food may be in the form of powder, tablet or liquid.

[0049] The food of the present invention can be produced by the preparation method commonly used in the art, which will not be described in detail here.

[0050] All descriptions above regarding the nutritional composition of the first aspect of the present invention apply hereto.

[0051] drug

[0052] The third aspect of the present invention provides a medicine comprising the nutritional composition according to the first aspect of the present invention.

[0053] The present invention has no special requirements for the dosage form of the drug, and the dosage form commonly used in the art can be used. As an example, the drug of the present invention can be a solid preparation, such as powder, granules, tablets, capsules, drop pills, pills, etc.; a semi-solid preparation, such as an ointment, cream, eye ointment, gel, etc.; a liquid preparation, such as an oral liquid preparation, such as a syrup, mixture, suspension, emulsion, etc.

[0054] It is easy for those skilled in the art to understand that the drug may also include various pharmaceutically acceptable excipients according to different drug dosage forms and application scenarios. In addition, the drug of the present invention can be prepared by methods commonly used in the art, which will not be described in detail here.

[0055] All descriptions above regarding the nutritional composition of the first aspect of the present invention apply hereto.

[0056] use

[0057] The fourth aspect of the present invention relates to the use of the nutritional composition according to the first aspect of the present invention or the food (eg, health food) according to the second aspect of the present invention for the non-therapeutic purpose of improving sleep.

[0058] The non-therapeutic purpose for improving sleep (non-medical therapeutic purpose such as nutrition and / or health care purpose) is, for example, for preparing food for improving sleep (such as functional food, health food, or health product).

[0059] In some embodiments, improving sleep may include, for example, improving the sleep quality of adults, adolescents, children, or infants, particularly improving the sleep quality of infants.

[0060] In some embodiments, improving sleep comprises improving (eg, reducing) the amount of wake activity and the total time awake.

[0061] As described above, MLCT and MFGM, when used in combination at a specific weight ratio, exhibit a synergistic effect in improving sleep, especially in terms of the amount of wakefulness activity and the total wakefulness time. The effect of their combined use is better than the effect of the same total amount of MLCT alone, and is also better than the effect of the same total amount of MFGM alone.

[0062] In an embodiment, when the nutritional composition or food (e.g., health food) is used for oral administration to humans, the dosage is such that: the dosage of the MLCT may be 0.1 to 30.0 g / day, preferably 0.4 to 30 g / day (e.g., 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12 .0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 15.5, 16.0, 16.5, 17.0, 17.5, 18.0, 18.5, 19.0, 19.5, 20.0, 20.5, 21.0, 21.5, 22.0, 22.5, 23.0, 23.5, 24.0, 24.5, 25.0, 25.5, 26.0, 26.5, 27.0, 27.5, 28.0, 28.5, 29.0, 29.5, 30.0 g / day, or a range defined by any two of them), and in a further embodiment, the dosage of MFGM is converted according to the ratio.

[0063] In some embodiments, the dosage of MFGM can be 0.1-30.0 g / day (e.g., 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0, 20.0, 21.0, 22.0, 23.0, 24.0, 25.0, 26.0, 27.0, 28.0, 29.0, 30.0 g / day, or a range defined by any two of them).

[0064] The fifth aspect of the present invention relates to use of the nutritional composition according to the first aspect of the present invention in the preparation of a medicine for improving sleep.

[0065] Improving sleep may include improving (eg, reducing) the amount of waking activity and the total time awake.

[0066] All the above descriptions about the nutritional composition of the first aspect of the present invention are applicable here and will not be repeated here.

[0067] Example In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0068] The sources and specifications of the raw materials used in the following examples are as follows: MLCT: medium-chain fatty acid edible oil produced by Qingdao Haizhiyuan Life Science Technology Co., Ltd. (production batch number is Y1505-22120101), wherein the purity of MLCT is 69±10% by weight; milk fat globule membrane (MFGM): purchased from Arla, the product name is Lacprodan® MFGM-10, the batch number is P510216, the phospholipid content in this raw material is 8±2% by weight, the protein content is 71.5±5% by weight, and the sphingomyelin g / 100g phospholipid is 25±10g; wild-type AB strain zebrafish: provided by the fish breeding center of Hangzhou Huante Biotechnology Co., Ltd.; L-Tryptophan (batch number 111521, Shanghai Taoshu Biotechnology Co., Ltd., China), purity 99.87%; Luzindole (batch number SLCM6972, Sigma, USA), purity ≥90%).

[0069] Animal experiments

[0070] Wild-type AB zebrafish of 5 days post-fertilization (5 dpf) were randomly selected and placed in a well plate. Thirty zebrafish were treated in each well, and 10 wells were repeated in each group. A normal control group, a model control group, a positive control group, an experimental control group, and an experimental group were set up in each experiment. Figure 1 , Figure 2 , Table 1), the positive control group L-Tryptophan concentration of 50.0 µg / mL, and the normal control group and model control group were set up at the same time, with a volume of 3 mL per well. After 1 day of treatment at 28°C, 10 zebrafish were randomly selected from each group and transferred to a 96-well plate, 1 tail / 200 μL / well. Except for the normal control group, all other experimental groups were given Luzindole (6.25 μg / mL) in water to establish a zebrafish insomnia model. The amount of awakening activity and total awakening time of zebrafish within 1 hour were measured using a behavioral analyzer, and the statistical analysis results of the above indicators were used to evaluate the sleep-improving efficacy of the samples. The statistical processing results were expressed as mean ± standard error (SE, Standard Error) (n = 10). SPSS26.0 software was used for statistical analysis, and p < 0.05 indicated that the difference was statistically significant.

[0071] 1. Use MLCT or MFGM alone

[0072] Figure 1 The results of statistical analysis of the awakening activity (A and C) and total awakening time (B and D) of zebrafish in the normal control group, model control group, positive control group using L-Tryptophan, and experimental control group using MLCT or MFGM alone are presented. Figure 1 A shows the results of the amount of wakefulness activity when different concentrations of MLCT were used alone, Figure 1 B shows the results of total wakefulness time when using different concentrations of MLCT alone, Figure 1 C shows the results of the amount of wakefulness activity when using different concentrations of MFGM alone, Figure 1 D shows the results of total wakefulness time when different concentrations of MFGM were used alone.

[0073] Depend on Figure 1 It can be seen that compared with the model control group, MLCT or MFGM alone led to a significant reduction in the total wakefulness time and the amount of wakefulness activity, which indicates that MLCT or MFGM alone has the effect of improving sleep.

[0074] For MLCT alone, in terms of wakefulness, the wakefulness was lowest at a concentration of 250 µg / mL; in terms of total wakefulness time, the total wakefulness time at a concentration of 250 µg / mL was significantly lower than that at a concentration of 172.5 µg / mL, and when the concentration was greater than 250 µg / mL, that is, at concentrations of 345 µg / mL and 690 µg / mL, the total wakefulness time was not significantly reduced compared with that at a concentration of 250 µg / mL (P>0.05). Therefore, 250 µg / mL is the optimal concentration of MLCT in improving sleep.

[0075] For MFGM alone, at a concentration of 250 µg / mL, the total wakefulness time and total wakefulness activity were significantly reduced compared to that at a concentration of 125 µg / mL, but when the concentration continued to increase, that is, at concentrations of 500 µg / mL and 1000 µg / mL, the total wakefulness time and total wakefulness activity were not significantly reduced compared to that at a concentration of 250 µg / mL. Therefore, the optimal concentration of MFGM in terms of its efficacy in improving sleep is also 250 µg / mL.

[0076] 2. Use of nutritional compositions including MLCT or MFGM

[0077] As the optimal concentration obtained from the above experiment, nutritional compositions including different proportions of MLCT or MFGM at a concentration of 250 µg / mL were studied. The results are shown in Table 1 and more intuitively shown in Figure 2 middle.

[0078] Table 1 Efficacy results of nutritional compositions for improving sleep (n = 10)

[0079]

[0080] Note: Compared with the model control group, *** represents p < 0.001.

[0081] Combining Table 1 and Figure 2 It can be seen that compared with the model control group, the amount of awakening activity and the awakening time of Examples 1 to 9 were significantly reduced, indicating that the nutritional composition including MLCT and MFGM has the effect of improving sleep.

[0082] Furthermore, when the MLCT:MFGM ratio is in the range of 0.2:1 (Example 2) to 40:1 (Example 8), the resulting awakening activity and awakening time are less than that of MLCT alone at the same concentration, and less than that of MFGM alone at the same concentration, indicating that MLCT and MFGM exhibit significant synergistic effects within the above concentration range.

[0083] Further, when MLCT:MFGM was in the range of 0.48:1 (Example 3) to 24:1 (Example 7), the resulting wakefulness activity amount and wakefulness time were smaller compared to other examples, indicating that the synergistic effect was further enhanced.

[0084] Further, when MLCT:MFGM was in the range of 0.48:1 (Example 3) to 7.74:1 (Example 6), the resulting wakefulness activity amount and wakefulness time were smaller compared to other examples, indicating that the synergistic effect was further enhanced.

[0085] Further, when MLCT:MFGM was in the range of 1:1 (Example 4) to 5:1 (Example 5), the resulting wakefulness activity amount and wakefulness time were smaller compared to other examples, indicating that the synergistic effect was further enhanced.

[0086] The above description is only an exemplary embodiment of the present invention. It should be noted that, for those skilled in the art, without departing from the creative concept of the present invention, the present invention can also be improved, but these all belong to the protection scope of the present invention.

Claims

1. A nutritional composition comprising: Medium and long chain fatty acid triglycerides; and milk fat globule membrane, It is characterized in that the weight ratio of the medium and long chain fatty acid triglycerides to the milk fat globule membrane is 0.1:1 to 50:

1.

2. The nutritional composition according to claim 1, characterized in that The weight ratio of the medium-chain fatty acid triglyceride to the milk fat globule membrane is 0.2:1 to 40:

1.

3. The nutritional composition according to claim 1, characterized in that The weight ratio of the medium-chain fatty acid triglyceride to the milk fat globule membrane is 0.4:1 to 24:

1.

4. The nutritional composition according to claim 1, characterized in that The weight ratio of the medium-chain fatty acid triglyceride to the milk fat globule membrane is 0.4:1 to 8:

1.

5. The nutritional composition according to claim 1, characterized in that The weight ratio of the medium-chain fatty acid triglyceride to the milk fat globule membrane is 1:1 to 5:

1.

6. Food, characterized in that It comprises the nutritional composition according to any one of claims 1-5.

7. The food according to claim 6, characterized in that The food is infant food.

8. The food according to claim 6, characterized in that The food is selected from dairy products, candies, beverages, bread and biscuits.

9. The food according to claim 6, characterized in that The food is milk powder or fermented food.

10. The food according to claim 9, characterized in that The milk powder is infant formula milk powder.

11. The food according to claim 6, characterized in that The food is a health food.

12. The food according to any one of claims 6 to 11, characterized in that It further comprises one or more selected from the following: raw cow milk, desalted whey powder, concentrated whey protein, lactose, edible vegetable blending oil, oligofructose, oligogalactose, nucleotide, choline, vitamins, minerals, DHA and taurine.

13. A medicine characterized in that It comprises the nutritional composition according to any one of claims 1-5.

14. Use of the nutritional composition according to any one of claims 1 to 5 or the food according to any one of claims 6 to 12 for the non-therapeutic purpose of improving sleep.

15. The use according to claim 14, characterized in that The improving sleep refers to improving the sleep of infants and young children.

16. The use according to claim 14, characterized in that The improved sleep includes improving the amount of wakefulness activity and the total wakefulness time.

17. Use of the nutritional composition according to any one of claims 1 to 5 in the preparation of a medicine for improving sleep.

Images